Plegomazin

Base Information

• Chemical Name: Plegomazin
• CAS No.: 69-09-0
• Molecular Formula: C17H19ClN2S.HCl
• Molecular Weight: 355.331
• Hs Code.: 29173980
• Mol file: 69-09-0.mol

Synonyms:Plegomazin;AKOS015895975;2-chloro-N,N-dimethyl-10H-phenothiazine-10-propanamine monohydrochloride

Chemical Property of Plegomazin

Chemical Property:

• Appearance/Colour: creamy white crystalline powder
• Melting Point: 192-196 °C
• Boiling Point: 450.1 °C at 760 mmHg
• Flash Point: 226 °C
• PSA: 31.78000
• Density: 1.077 g/cm3 (15 C)
• LogP: 5.76140
• Storage Temp.: -20°C Freezer
• Solubility.: Very soluble in water, freely soluble in ethanol (96 per cent). It decomposes on exposure to air and light.
• Water Solubility.: >=10 g/100 mL at 24 ºC
• Hydrogen Bond Donor Count: 1
• Hydrogen Bond Acceptor Count: 4
• Rotatable Bond Count: 4
• Exact Mass: 354.0724252
• Heavy Atom Count: 22
• Complexity: 339

Purity/Quality:

98%, ^*data from raw suppliers

Chlorpromazine Hydrochloride ^*data from reagent suppliers

Safty Information:

• Pictogram(s): T+
• Hazard Codes: T+,T,F
• Statements: 25-26-39/23/24/25-23/24/25-11
• Safety Statements: 28-36/37-45-16

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: [H+].CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl.[Cl-]
• Uses: Chlorpromazine hydrochloride is used in the treatment of schizophrenia; anti-emetic; as an antipsychotic in pills, injections, and suppositories; to relieve nausea and vomiting associated with malignant diseases. In veterinary medicine, it is used as an anti-emetic, tranquilizer and sedative. It has slight antihistaminic and anti adrenaline actions. It is a peripheral vasodilator and adepressant that blocks dopamine receptors in the central nervous system. Antiemetic;Dopamine antagonist Used as an Antiemetic, Antipsychotic
• Therapeutic Function: Tranquilizer
• Clinical Use: #N/A
• Drug interactions: Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect. Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids; increased risk of ventricular arrhythmias with methadone. Anti-arrhythmics: increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval and disopyramide; avoid with amiodarone and dronedarone. Antibacterials: increased risk of ventricular arrhythmias with delamanid, moxifloxacin and telithromycin - avoid with moxifloxacin. Antidepressants: increased level of tricyclics, possibly increased risk of ventricular arrhythmias and antimuscarinic side effects; increased risk of ventricular arrhythmias with citalopram and escitalopram - avoid; increased risk of convulsions with vortioxetine. Anticonvulsants: antagonises anticonvulsant effect; concentration of fosphenytoin and phenytoin possibly increased or decreased; concentration of both drugs reduced with phenobarbital. Antimalarials: avoid with artemether/lumefantrine and piperaquine with artenimol. Antipsychotics: increased risk of ventricular arrhythmias with droperidol and pimozide - avoid; concentration of haloperidol possibly increased; possible increased risk of ventricular arrhythmias with risperidone. Antivirals: concentration possibly increased with ritonavir; increased risk of ventricular arrhythmias with saquinavir - avoid. Anxiolytics and hypnotics: increased sedative effects. Atomoxetine: increased risk of ventricular arrhythmias.Beta-blockers: enhanced hypotensive effect; concentration of both drugs may increase with propranolol; increased risk of ventricular arrhythmias with sotalol. Cytotoxics: increased risk of ventricular arrhythmias with vandetanib - avoid; increased risk of ventricular arrhythmias with arsenic trioxide. Diuretics: enhanced hypotensive effect. Lithium: increased risk of extrapyramidal side effects and possibly neurotoxicity. Pentamidine: increased risk of ventricular arrhythmias. Ulcer-healing drugs: effects enhanced by cimetidine.

Technology Process of Plegomazin

There total 3 articles about Plegomazin which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 98.7%

2-chlorophenothiazine (92-39-7) + 3-(Dimethylamino)propyl chloride (109-54-6) → chlorpromazine hydrochloride (69-09-0)

Guidance literature:

2-chlorophenothiazine; 3-(Dimethylamino)propyl chloride; With dmap; In 1-methyl-pyrrolidin-2-one; for 4h; Reflux;

With hydrogenchloride; In water; isopropyl alcohol; at 55 ℃; for 2h; Reagent/catalyst; Solvent; Temperature;

Reference yield: 85.0%

2-chlorophenothiazine (92-39-7) + 3-(dimethylamino)propyl chloride hydrochloride (5407-04-5) → chlorpromazine hydrochloride (69-09-0)

Guidance literature:

With potassium hydroxide; Aliquat 336; at 80 ℃; for 1h;

DOI:10.1248/cpb.33.5108

Reference yield:

oxovanadium(IV) sulfate + chloropromazine cation radical (50-53-3) → chlorpromazine hydrochloride (69-09-0) + vanadium(5+) (22537-31-1)

Guidance literature:

In water; deoxygenated solutions, 25.0-38.7°C, 0.1 to 1.0 M - H(1+); not isolated, detd. by stopped-flow UV/VIS spectroscopy; Kinetics;

DOI:10.1016/S0020-1693(00)87887-1

upstream raw materials:

2-chlorophenothiazine

3-(dimethylamino)propyl chloride hydrochloride

chloropromazine cation radical

3-(Dimethylamino)propyl chloride

Downstream raw materials:

promazine Hydrochloride

vanadium(IV) cation

chloropromazine cation radical

3-(2-chloro-10H-phenothiazin-10-yl)-N,N,N-trimethylpropan-1-aminium iodide

Refernces

• 1、 Galons,Miocque,Combet-Farnoux,et al.. "A convenient procedure for the synthesis of phenothiazine drugs". . p. 5108 - 5109. Retrieved 2007/10/02.